Summary
Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored. Paranoid ideas disappeared in all seven patients after a maximum of four days administration of 25–125 mg/day. No deterioration of parkinsonian symptoms, quantified according to UPDRS was seen. Given the protection of clozapine, we could increase the L-dopa dose in two cases, thereby improving the patients' motor function. Blood count showed no abnormalities in any of the patients during an average observation period of seventeen months.
Our results support the assumption that clozapine has a potent antipsychotic effect in the treatment of psychotic decompensation in advanced Parkinson's disease in carefully selected patients. We saw no negative influence of the neurolpetic on extrapyramidal symptoms.
Similar content being viewed by others
References
Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16: 517–525
Amsler HA, Teerehovi L, Barth E, Harjula K, Vuopio P (1977) Agranulocytosis in patients treated with clozapine. A study of the Finish epidemic. Acta Psychiatr Scand 56(4): 241–248
Anden N-E, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25: 346–348
Barbeau A (1969) L-Dopa therapy in Parkinson's disease, a critical review of nine years experience. Can Med Assoc J 101: 781–800
Barbeau A (1975) Résultats à long terme de la lévodopa dans la maladie de Parkinson. Union Med Con 104: 32–38
Birkmayer W (1966) Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien Z Nervenheilkunde 23: 128–139
Birkmayer W, Neumayer E (1972) Die Behandlung der Dopa-Psychosen mit L-Tryptophan. Nervenarzt 43: 76–78
Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie, 2. Aufl. Springer, Wien New York S190–196
Birkmayer W, Linauer W, Mentasti M (1971) Traitment à la L-Dopa combinée avec un inhibiteur der la decarboxylase (Ro 4-4602). In: de Ajuriaguerra J, Gauthier G (eds) Monoamines, noyaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 435–441
Birkmayer W, Danielczyk W, Riederer P (1983) Symptoms and side effects in the course of Parkinson's disease. J Neural Transm [Suppl 19]: 185–199
Bowers MB, Rozitis A (1974) Regional differences in homovanillic acid concentration after acute and chronic administration of antipsychotic drugs. J Pharm Pharmacol 26: 743–745
Bürki HR (1986) Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn-Schmiedebergs Arch Pharmacol 332: 258–266
Bürki HR, Eichenberger E, Sayers AC, White TG (1975) Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmacopsychiatry 8: 115–121
Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135: 164–173
Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: 47–53
Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestation of levodopa therapy. Arch Neurol 23: 193–200
Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 33: 577–583
Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, et al (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384
Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA (1988) Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull 24: 269–274
Damasio AR, Lobo-Antunes J, Macedo C (1981) Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 34: 502–507
De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45: 1161–1164
Eichenberger E (1984) Pharmacology of fluperlapine compared with clozapine. Arzneimittelforschung 34: 110–113
Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989) Clozapine: an atypical antipsychotic agent. Clin Pharm 8: 691–709
Fahn S, Elton RL and Members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinson disease, vol II, MacMillan Healthcare Information, Florham Park NJ, pp 153–163
Fischer PA, Baas H, Hefner R (1990) Treatment of parkinsonian tremor with clozapine. J Neural Transm [PD-Sect] 2: 233–238
Friedman JH, Lannon MC (1989) Clozapine in treatment of psychosis in Parkinson's disease. Neurology 39: 1219–1221
Friedman JH, Max J, Switf R (1987) Idiopathic Parkinson's disease in chronic shizophrenic patient: long-term treatment with clozapine and L-Dopa. Clin Neuropharmacol 10: 470–475
Gehlen W, Müller J (1974) Zur Therapie der Dopa-Psychosen mit L-Tryptophan. Dtsch Med Wochenschr 99: 457–463
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Idänpään-Heikkilä J, Alhava E, Olkinnora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11: 193–198
Kahn NA (1990) Clozapine for psychosis in Parkinson's patients. Clin Adv Treat Psychiatr Disord 4: 12–16
Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796
Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460: 398–491
Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260
Lieberman A, Kupersmith M, Neophytides A (1980) Bromocriptine in Parkinson's disease: report on 106 patients treated up to 5 years. In: Calne DB, Goldstein M, Lieberman A, Thorner M (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 245–253
Liebermann A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D (1981) Treatment of advanced Parkinson disease with pergolide. Neurology 31: 675–682
Ludin HP (1988) Das Parkinsonsyndrom. In: Baumgartner G, Cohen R, Grüsser OJ, Helmchen H, Schmidt LR (Hrsg) Kohlhammer, Stuttgart Berlin Köln Mainz, S104
Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet i: 345–349
Marsden CD, Fahn S (1981) Problems in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 1–7
Mindham RHS (1970) Psychiatric syndromes in parkinsonism. J Neurol Neurosurg Psychiatry 30: 188–191
Mindham RHS (1974) Psychiatric aspects of Parkinson's disease. Br J Hosp Med II: 411–414
Moskovitz C, More H, Klawans H (1978) Levodopa induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 218–226
Ostergaard K, Dupont E (1988) Clozapine treatment of drug induced psychotic symptoms in the late stages of Parkinson's disease. Acta Neurol Scand 78: 349–350
Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73: 295–297
Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson's disease. Mov Disord 5: 239–242
Povlsen UJ, Noring U, Fog R, Gerlach J (1985) Toerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71: 176–185
Roberts HE, Dean RC, Stoudemire A (1989) Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatr Clin Neurosci 1: 190–192
Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinsonsyndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiatr 52: 207–214
Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64
Serby M, Angrist B, Leberman A (1978) Mental disturbances during bromocriptine and lergotile treatment of Parkinson's disease. Am J Psychiatry 135: 1227–1229
Snyder S, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarini sites predicts extrapyramidal effects. Arch Gen Psychiatry 31: 58–61
Stern Y, Mayeux R, Ilson J, Fahn S, Cote L (1984) Pergolide therapy for Parkinson's disease: neurobehavioural changes. Neurology 34: 201–204
Tanner CM, Vogel C, Goetz CG, Klawans HL (1983) Hallucinations in Parkinson's disease: a population study. Ann Neurol 14: 136
Watling KJ, Beer MS, Stanton JA, Newberry NR (1990) Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 183: 465–472
Westerink BHC, Lejeune B, Korf J, Van Praag HM (1977) On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol 42: 179–190
Wolters ECh, Hurwitz TA, Peppard RF, Calne DB (1989) Clozapine: an antipsychotic agent in Parkinson's disease? Clin Neuropharmacol 12: 83–90
Wolters ECh, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, Calne S, Calne DM (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40: 832–834
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pinter, M.M., Helscher, R.J. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Gen Sect 5, 135–146 (1993). https://doi.org/10.1007/BF02251204
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02251204